Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 3/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | KDM1A | O60341 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4799446 | 1.00 | CA14 (0.43) | CA14CA2CA12CA1CA9 | |
| SCHEMBL6464487 | 1.00 | CA14 (0.43) | CA14CA2CA12CA1CA9 | |
| SCHEMBL18198036 | 0.78 | CA14 (0.41) | CA14CA12CA1CA9 | |
| SCHEMBL18198035 | 0.78 | CA14 (0.41) | CA14CA12CA1CA9 | |
| SCHEMBL18198032 | 0.78 | CA14 (0.41) | CA14CA12CA1CA9 | |
| SCHEMBL18047580 | 0.77 | ADAMTS4 (0.44) | CA14CA2CA12CA1 | |
| SCHEMBL8354666 | 0.77 | CA14 (0.39) | CA14CA2CA12 | |
| SCHEMBL15473444 | 0.77 | CA14 (0.39) | CA14CA2CA12 | |
| SCHEMBL697449 | 0.77 | ADAMTS4 (0.44) | CA14CA2CA12CA1 | |
| SCHEMBL697448 | 0.77 | ADAMTS4 (0.44) | CA14CA2CA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160318932-A1 | PYRIDONE-SULFONE MORPHINAN ANALOGS AS OPIOID RECEPTOR LIGANDS | PURDUE PHARMA L.P. | 2016-11-03 | — | — | US | disclosed |
| WO-2015102682-A1 | PYRIDONE-SULFONE MORPHINAN ANALOGS AS OPIOID RECEPTOR LIGANDS | PURDUE PHARMA L.P. (US) | 2015-07-09 | — | — | WO | disclosed |
| EP-1891003-A1 | FLUOROALKYLAMINE DERIVATIVES AS CATHEPSIN INHIBITORS | Merck Frosst Canada Ltd. (CA) | 2008-02-27 | — | — | EP | disclosed |
| WO-2006128287-A1 | FLUOROALKYLAMINE DERIVATIVES AS CATHEPSIN INHIBITORS | MERCK FROSST CANADA LTD. (CA) | 2006-12-07 | — | — | WO | disclosed |
| EP-1452522-A2 | Novel compounds and compositions as protease inhibitors | AXYS PHARMACEUTICALS, INC. (US) | 2004-09-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160318932-A1 | PYRIDONE-SULFONE MORPHINAN ANALOGS AS OPIOID RECEPTOR LIGANDS | OPRK1, OPRM1, OPRL1 | CA14 4743/4885CA2 4457/4885CA12 4863/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.